Abstract
AbstractThe causal mechanisms and treatment for the negative symptoms and cognitive dysfunction in schizophrenia are the main issues attracting the attention of psychiatrists over the last decade. The first part of this review summarizes the pathogenesis of schizophrenia, especially the negative symptoms and cognitive dysfunction from the perspectives of genetics and epigenetics. The second part describes the novel medications and several advanced physical therapies (e.g., transcranial magnetic stimulation and transcranial direct current stimulation) for the negative symptoms and cognitive dysfunction that will optimize the therapeutic strategy for patients with schizophrenia in future.
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Physiology,General Neuroscience
Reference207 articles.
1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016, 388: 86–97.
2. Rund BR, Barder HE, Evensen J, Haahr U, ten Velden Hegelstad W, Joa I. Neurocognition and duration of psychosis: A 10-year follow-up of first-episode patients. Schizophr Bull 2016, 42: 87–95.
3. Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: A population-based study. BMC Psychiatry 2014, 14: 225.
4. Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. J Clin Psychiatry 2010, 71: 280–286.
5. Mäkinen J, Miettunen J, Isohanni M, Koponen H. Negative symptoms in schizophrenia: A review. Nord J Psychiatry 2008, 62: 334–341.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献